ArticleExperimental & molecular medicine2025
Platelet-rich plasma-derived exosomes establishing a muscular proregenerative microenvironment through enhancing the viability of fibro-adipogenic progenitors.
Article in Experimental & molecular medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Exercise rejuvenates the "muscle-heart" crosstalk: skeletal muscle-derived exosomal miRNAs in cardiac aging.Frontiers in cardiovascular medicine · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
18 authors.
Funding
Abstract
Clinical studies have shown a paradox of the usage of platelet-rich plasma (PRP) on treating fatty infiltration (FI) in injured muscles. However, the underlying reason is still unclear, partially owing to unknown effective components and confounders. Here we found that exosomes derived from PRP (thereafter named PRP-exos) most efficiently prevented FI in injured muscles by inhibiting the adipogenesis of fibro-adipogenic progenitors (FAPs). Importantly, we found aging largely impaired the therapeutic effects of PRP-exos. Mechanistically, miRNA cargoes in PRP-exos mediated the effects of PRP-exos on adipogenesis of FAPs as well as FI in injured muscles, of which, hsa-let-7f-5p and hsa-miR-16-5p were the two most important components. TGFBR3 was identified as a new cotarget gene of these two miRNAs and a new regulator to control the adipogenesis of FAPs. The FI in muscles can be significantly reduced after conditional knockout of TGFBR3 in FAPs. In addition, we further investigated that TGFBR3 regulated the activation of ERK-PPARγ pathway through directly inducing the degradation of KRT10, and thus impacted the adipogenesis of FAPs. Interestingly, PRP-exos or these two miRNAs can preserve the viability and promote the proregenerative supporting capacity of FAPs by targeting TGFBR3 to facilitate muscle regeneration. Collectively, our findings identified the effective components in PRP to inhibit FI and support muscle regeneration. Furthermore, the negative influence of aging on clinical applications of PRP cannot be neglected.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.